New radioactive therapy targets Hard-to-Treat brain tumors
NCT ID NCT07150806
First seen Sep 30, 2025 · Last updated May 18, 2026 · Updated 29 times
Summary
This study tests a radioactive drug called RYZ101 for people with meningioma brain tumors that have come back or are growing despite standard treatments. The drug targets a protein found on these tumor cells and delivers radiation to kill them. The trial involves 30 adults and aims to find the best dose, check safety, and see if it can stop the tumor from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.